Get the skinny on this. Novo Nordisk, the Danish pharmaceutical company that manufactures Ozempic, said that it is “very likely” the cost of the popular diabetes-turned-weight loss drug will be cut in the second round of Medicare drug price negotiations.

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first cycle of negotiations.

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program, a company executive said.